바로가기메뉴

본문 바로가기 주메뉴 바로가기

Journal of the Korean Association of Oral and Maxillofacial Surgeons

  • P-ISSN2234-7550
  • E-ISSN2234-5930
  • SCOPUS, KCI, ESCI

Successful treatment of adjunctive teriparatide therapy for medication-related osteonecrosis of the jaw: a report of two cases

Journal of the Korean Association of Oral and Maxillofacial Surgeons / Journal of the Korean Association of Oral and Maxillofacial Surgeons, (P)2234-7550; (E)2234-5930
2024, v.50 no.5, pp.285-291
https://doi.org/10.5125/jkaoms.2024.50.5.285
Kim Ra-yeon (Department of Oral and Maxillofacial Surgery, Kyung Hee University Dental Hospital at Gangdong, Kyung Hee University College of Dentistry, Seoul, Korea)
Hong Sung ok (Department of Oral and Maxillofacial Surgery, Kyung Hee University Dental Hospital at Gangdong, Kyung Hee University College of Dentistry, Seoul, Korea)
Jung Jae-woong (Department of Oral and Maxillofacial Surgery, Kyung Hee University Dental Hospital at Gangdong, Kyung Hee University College of Dentistry, Seoul, Korea)
Lee Mu-hang (Department of Oral and Maxillofacial Surgery, Kyung Hee University Dental Hospital at Gangdong, Kyung Hee University College of Dentistry, Seoul, Korea)
Lee Young-kee (Department of Oral and Maxillofacial Surgery, Kyung Hee University Dental Hospital at Gangdong, Kyung Hee University College of Dentistry, Seoul, Korea)
Jee Yu-jin (Department of Oral and Maxillofacial Surgery, Kyung Hee University Dental Hospital at Gangdong, Kyung Hee University College of Dentistry, Seoul, Korea)

Abstract

Medication-related osteonecrosis of the jaw (MRONJ) is a refractory disease that can lead to severe destruction of the jaw. As there is no standard protocol for treating MRONJ, various treatments have been studied. Teriparatide has been used as an adjunct therapy for MRONJ. However, its effectiveness has not been sufficiently demonstrated for use as a standard treatment for MRONJ. This study aimed to demonstrate the efficacy of teriparatide in treating MRONJ by presenting two successfully treated cases. Each patient received teriparatide therapy with surgical intervention. The appropriateness of teriparatide use was evaluated based on the patient’s systemic condition, and the administration of teriparatide was supervised by a physician. Complete resolution of the lesion was observed clinically and radiographically in both patients. The first patient underwent implant placement at the lesion site. Due to its anabolic properties and ability to stimulate bone remodeling, teriparatide is an effective adjunctive pharmacological treatment for bone healing before and after surgery with associated beneficial effects on bone and mucosal healing.

keywords
Bisphosphonate-associated osteonecrosis of the jaw, Teriparatide, Parathyroid hormone, Osteoporosis

Journal of the Korean Association of Oral and Maxillofacial Surgeons